Alivus Life Sciences Ltd Submits Integrated Annual Report for FY25, Showing 4.5% Revenue Growth and 3.1% EPS Increase

Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd, has submitted its Integrated Annual Report for the Financial Year 2024-25. The report, prepared in accordance with the International Integrated Reporting Council's (IIRC) Framework, presents a unified perspective of the company's performance across six capitals: Financial, Manufactured, Intellectual, Human, Social & Relationship, and Natural. The company has reported a 4.5% increase in revenue from operations, a 23.8% increase in net cash from operations, and a 3.1% increase in EPS. The report also highlights the company's focus on long-term value creation, innovative capabilities, and integrated thinking.